Navigation Links
Surveyed European Oncologists Assign Greater Patient Share to Johnson & Johnson's Abiraterone Compared With Other Emerging Therapies in Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
Date:9/30/2010

tant prostate cancer (NMCRPC), Amgen's Prolia has considerable commercial potential assuming it can gain approval as an anti-neoplastic agent (and improve bone metastases-free survival). Significant commercial potential in the NMCRPC setting arises from the large drug-treatable pool and potentially long treatment durations.

The report also finds that abiraterone use in the asymptomatic setting is the only emerging therapy in NMCRPC or first-line MCRPC which is likely to secure a favorable NICE appraisal, according to the majority of surveyed oncologists in the United Kingdom. Interviewed payers indicate that the premium prices of emerging therapies, (notably Revlimid and Provenge) may limit uptake although generic docetaxel will help stimulate use of emerging therapies used in combination with docetaxel because of an overall reduced cost of the regimen.

The report is based on a survey of 251 oncologists from Germany (50), France (50), Italy (51), Spain (50) and the United Kingdom (50) and interviews with 15 European payers from Germany (3), France (3), Italy (3), Spain (3) and the United Kingdom (3).

About Decision ResourcesDecision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or regis
'/>"/>

SOURCE Decision Resources
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Surveyed Oncologists Say That the Most Promising Targeted Therapy in Adjuvant Clinical Trials is Avastin for the Treatment of Early-Stage Colorectal Cancer
2. Surveyed Neurologists Anticipate That Less Than 30 Percent of Their Use of Emerging Oral Agents in Multiple Sclerosis Will be in the First Line
3. Carbapenems and Other Agents that Provide Broad-Spectrum Activity are Preferred by Surveyed Physicians for the Treatment of Intra-Abdominal Infections
4. Ninety Eight Percent of Surveyed Rheumatologists Will Prescribe Roches Actemra for Rheumatoid Arthritis
5. Surveyed European Oncologists Cite Cost Most Frequently as the Factor Preventing Their Use of Avastin for Non-Small-Cell Lung Cancer
6. Majority of Surveyed Pharmacy Directors Expect To Cover Pfizers Tanezumab If It Is Approved for the Treatment of Chronic Pain
7. An Acute Migraine Therapy That is Not Contraindicated in Patients With a History of Vascular Disease Would Earn a 45 Percent Patient Share in the United States, According to Surveyed Neurologists
8. In First- and Second-Line Treatment of Clostridium Difficile Infection, Nearly 70 Percent of Surveyed Infectious Disease Specialists and Internists Will Use Fidaxomicin and Nearly Half Will Use CDA1/CDB1
9. For Treatment of Non-Hodgkins Lymphoma and Chronic Lymphocytic Leukemia, 41 Percent of Surveyed European Hematologist-Oncologists Say MabTheras Favorable Efficacy Profile is the Most Significant Driver of Their Use of This Agent
10. For Multiple Myeloma Treatment, More Surveyed European Clinicians Consider the Combination of Immunomodulatory Agents and Proteasome Inhibitors Promising With Respect to Efficacy Than Any Other Drug Regimen Combinations
11. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... Concord Medical Services Holdings Limited ("Concord Medical" or the ... hospital management solution provider and operator of the largest ... China , today announced that on July ... cash dividend of US$0.30 per ordinary share (or US$0.90 ... ordinary shares. The total expense for the special dividend ...
(Date:7/28/2014)... CHAPEL HILL, N.C. , July 28, 2014 /PRNewswire/ ... results of a clinical trial demonstrating that CXL-1427, a ... was well tolerated in healthy volunteers. The company has ... failure in a Phase IIa clinical trial designed to ... as its dosing levels. The Phase I ...
(Date:7/28/2014)... 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ISIS ... Financial Results and Highlights Conference CallWhen:Monday, August 4 at ... How:Live on the Internet. Simply log onto our website ... the live event, a replay of the webcast will ... . ABOUT ISIS PHARMACEUTICALS, INC. Isis is ...
Breaking Medicine Technology:Concord Medical Declares Special Dividend 2Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427 2Webcast Alert: Isis Pharmaceuticals' Second Quarter 2014 Financial Results Conference Call 2
... allergic,asthma attacks and further define Xolair safety profile in ... up to their 12th birthday, - Xolair is ... associated,with approximately 78% of childhood asthma, - Allergic ... the age,of 18, - Xolair is currently approved ...
... SPEX ) reported that patient recruitment for its ... drug, Naturlose(R), has begun in,India. Expectations for India are ... for the pivotal Phase 3 trial. "Now that enrollment ... 3 trial will be completed,on schedule as reported during ...
Cached Medicine Technology:Study Shows Potential Benefits of Xolair(R) in Treating Children Suffering from Moderate or Severe Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids 2Study Shows Potential Benefits of Xolair(R) in Treating Children Suffering from Moderate or Severe Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids 3Study Shows Potential Benefits of Xolair(R) in Treating Children Suffering from Moderate or Severe Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids 4Study Shows Potential Benefits of Xolair(R) in Treating Children Suffering from Moderate or Severe Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids 5Study Shows Potential Benefits of Xolair(R) in Treating Children Suffering from Moderate or Severe Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids 6Study Shows Potential Benefits of Xolair(R) in Treating Children Suffering from Moderate or Severe Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids 7Patient Recruitment Begins in India for Phase 3 Diabetes Trial 2
(Date:7/28/2014)... 28, 2014 (HealthDay News) -- British researchers report that ... fewer germs around. In their experiments, the scientists ... germs from one person to the other than what ... more casual exchange might suffice as a cultural substitute ... are published in the August issue of the ...
(Date:7/28/2014)... July 28, 2014 Parker Waichman LLP, a ... to ensure that the heroes of 9/11 are never forgotten, ... announced an important deadline. According to a VCF message ... a covered cancer on or before October 12, 2012 must ... First responders and others who were allegedly injured by the ...
(Date:7/28/2014)... HealthDay Reporter MONDAY, July ... relieve sleep apnea in children, but a new study confirms ... if they,re already overweight. The researchers said that,s a ... of health problems -- including, ironically, sleep apnea. But they,re ... Instead, they said, doctors and parents should be aware that ...
(Date:7/28/2014)... (PRWEB) July 28, 2014 Sarasota-based FCCI ... Best Companies To Work For. Still headquartered in Sarasota ... the only Florida-domiciled company in the top ten of ... Companies list appears in the August issue of Florida ... and large employer categories. Ranked #7 for 2014, FCCI ...
(Date:7/28/2014)... improving treatment for patients with one of the UK,s ... boost. , Chronic obstructive pulmonary disease (COPD) is the ... difficulties due to long-term damage to the lungs. ... per cent of all hospital admissions in the UK, ... hospital after they are discharged. , A ...
Breaking Medicine News(10 mins):Health News:'Fist Bump' May Beat Handshake for Cleanliness 2Health News:'Fist Bump' May Beat Handshake for Cleanliness 3Health News:October 12, 2014 Deadline Approaching for 9/11 First Responders Suffering from Certain Cancers to Submit Their Registration to the VCF, Parker Waichman LLP Comments 2Health News:October 12, 2014 Deadline Approaching for 9/11 First Responders Suffering from Certain Cancers to Submit Their Registration to the VCF, Parker Waichman LLP Comments 3Health News:Tonsillectomy for Sleep Apnea May Trigger Weight Gain 2Health News:Tonsillectomy for Sleep Apnea May Trigger Weight Gain 3Health News:FCCI Insurance Group Makes Top 100 Best Companies List – and is the Only Florida-Headquartered Company in Top Ten 2Health News:FCCI Insurance Group Makes Top 100 Best Companies List – and is the Only Florida-Headquartered Company in Top Ten 3Health News:New research to tackle treatment for lung disease 2Health News:New research to tackle treatment for lung disease 3
... termed ripples and fast ripples, recorded by intracranial ... the localization of the brain region responsible for ... in Epilepsia , a journal of the ... brain regions containing fast ripples, along with the ...
... clinical associate professor of psychiatry and director of the ... School of Medicine (BUSM), has been selected as the ... Training by the Association of Psychology Postdoctoral and Internship ... during the American Psychological Association,s Convention in Washington, DC, ...
... HealthDay Reporter , THURSDAY, July 28 (HealthDay News) -- The ... -- pregnancy has increased dramatically in recent years, according to ... the rate of pregnancy-related stroke hospitalizations went up by 54 ... see some increase in pregnancy-related stroke, but we did not ...
... , THURSDAY, July 28 (HealthDay News) -- Children ... of developing blood cancers -- such as leukemia, multiple ... new study contends. The researchers pointed out that ... and effect can be established, but they suggested that ...
... University of North Carolina-led international study shows that among ... of human papillomavirus-associated precancerous lesions of the penis. Human ... that plays an important role in genital cancers in ... cervix. Jennifer Smith, PhD, senior author, says, "Our ...
... July 28 (HealthDay News) -- Increasing your muscle mass can ... study suggests. Researchers analyzed data from 13,644 adults who ... Survey III between 1988 and 1994. They found that for ... -- the ratio of muscle mass to total body weight ...
Cached Medicine News:Health News:Fast ripples confirmed to be valuable biomarker of area responsible for seizure activity in children 2Health News:Pregnancy-Related Strokes Jump 54 Percent 2Health News:Pregnancy-Related Strokes Jump 54 Percent 3Health News:Growing Up Near Livestock Tied to Blood Cancers 2Health News:Male circumcision lowers prevalence of penile precancerous lesions among African men 2
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: